A Phase 1 interventional study of E-CEL UVEC in Anal Fistula, sponsored by Weill Medical College of Cornell University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.
Among the 20 studies in Rectal Fistula with a site in United States, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 1, and was the 11th registered.
170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.
Browse Rectal Fistula studies →7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:
ECM Therapeutics, Inc. · Sites in United States
Ages 18+
Signum Surgical USA Inc. · Sites in United States
Ages 18–75
RedDress Ltd. · Sites in United States, Israel
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Aroa Biosurgery Limited · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 66 across 116 interventional studies indexed under Rectal Fistula.
Median enrollment 21 across the 15 interventional studies, 79 across the 5 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 1 study filed under Rectal Fistula — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Fistula with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04190862Weill Medical College of Cornell UniversityE-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas | 2026-12-30 |
| NCT07021742Signum Surgical USA Inc.BioHealx® Anal Fistula Device Post Market Surveillance Study | 2027-02 |
| NCT07035925ECM Therapeutics, Inc.Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas | 2027-02-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Rectal Fistula with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.
The purpose of this study is to test the safety of E-CEL UVEC® cells and see what effects (good and bad) it has on your anal fistula. It is hoped, that the E-CEL UVEC® cells may help to improve healing of your fistula after surgery.
E-CEL UVEC® cells are genetically engineered human endothelial cells that are taken from the umbilical cords of newborn babies. The endothelial cells are cells that line the inside of blood vessels including the umbilical cord. Human umbilical endothelial cells are collected from the umbilical cord of a healthy newborn baby. The cells are obtained under strict United States (U.S.) Food and Drug Administration (FDA) regulations. The endothelial cells are engineered in the laboratory, meaning an extra gene is added. A gene is taken from a virus (just a single gene, not the entire virus) and inserted into the endothelial cells.This causes the endothelial cells to be more stable and improves their growth capabilities. In animal studies, the endothelial cells were cleared from the body within a month. No negative side effects related to the endothelial cells were seen in animal studies. A higher than normal healing response was seen in animal studies.
This research study is being done because, in animal studies, E-CEL UVEC® cells have been shown to speed up healing in various tissues and organs. This study will test if it is safe to use E-CEL UVEC® cells and if they help to improve healing of your fistula after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
Drug: E-CEL UVEC
Adult subjects with simple perianal fistula who meet all eligibility criteria to participate in Part B of the study will be treated in the outpatient setting with curettage and E-CEL UVEC cells without fistulotomy. E-CEL UVEC cells will be injected along the two sides (180 degrees apart from each other) of the whole length of the curetted anal fistula tract.
Drug: E-CEL UVEC
Subjects in Part B2-S will have the same eligibility criteria and would undergo the same procedure as described in Part B1, except that B2-S subjects will also have suturing and injection of the internal opening.
Drug: E-CEL UVEC
Subjects in Part BM1 will have the same eligibility criteria and would undergo the same procedure as described in Part B1, except that B2-M subjects in this cohort are eligible for up to 4 treatments (versus 1 in Part BS2).
Drug: E-CEL UVEC
This cohort comprises of multiple (M) treatments with E-CEL UVEC injections. The difference between Part BM1 and Part BM2, is that the subjects in the latter cohort receive double the dose of E-CEL UVEC cells per treatment. Subjects in Part BM2 will have the same eligibility criteria as Part BS1, BS2 and BM1 cohorts and would undergo the same treatment procedure as described in Parts BS1, BS2 and BM1. Every treatment consists of the percutaneous injection along both sides of the fistula tract plus injection of the internal opening via direct anoscopic visualization (described in the next paragraph). Dosing is 30 x 106 viable E-CEL UVEC cells into the area of the internal opening and minimum 30 x 106 viable E-CEL UVEC cells per centimeter along the fistula tract (15x106 viable E-CEL UVEC cells, each side per centimeter of the tract). All subjects in this cohort receive up to 6 treatments over 6 months. The six treatments are administered on visits WK 0, 3. 6, 9, 12 and 24.
Drug: E-CEL UVEC
Injection of E-CEL UVEC
The incident rate of treatment emergent adverse event in subjects with anal fistula (Part A)
Time frame: 2 weeks after surgery
The incident rate of treatment emergent adverse event in subjects with anal fistula (Part B)
Time frame: 3 weeks after surgery
Incidence rate of treatment emergent adverse events attributable to investigational therapy (Part B)
Time frame: Up to 24 weeks after surgery
The incident rate of treatment emergent adverse event in subjects with anal fistula (Part A)
Time frame: 6 weeks after surgery
The incident rate of treatment emergent adverse event in subjects with anal fistula (Part A)
Time frame: 24 weeks after surgery
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula (Part A)
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula at week 24 Relapse is defined as meeting relapse criteria No.1 and one of the three sub-criteria of relapse criteria No.2 1. Reopening of internal opening a. Defined as visual confirmation of new aperture or interruption of the anal mucosa at the previously closed internal opening site, plus 2. Any one of the three (a, b, or c) sub-criteria immediately below: a. New discharge upon digital pressure i. Defined as expression of gas, fecal matter or pus upon gentle digital pressure over and around the external opening or site of closed external opening, but excluding serous or serosanguinous fluid, or b. Emergence of palpable mass at or adjacent to the fistulous tract, or c. Emergence of pain measured at VAS ≥ 50 (out of 100) or NRS ≥ 5 (out of 10) associated with fistula tract, discharge, or bowel movement.
Time frame: 6 weeks after surgery
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula (Part A)
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula at week 24 Relapse is defined as meeting relapse criteria No.1 and one of the three sub-criteria of relapse criteria No.2 1. Reopening of internal opening a. Defined as visual confirmation of new aperture or interruption of the anal mucosa at the previously closed internal opening site, plus 2. Any one of the three (a, b, or c) sub-criteria immediately below: a. New discharge upon digital pressure i. Defined as expression of gas, fecal matter or pus upon gentle digital pressure over and around the external opening or site of closed external opening, but excluding serous or serosanguinous fluid, or b. Emergence of palpable mass at or adjacent to the fistulous tract, or c. Emergence of pain measured at VAS ≥ 50 (out of 100) or NRS ≥ 5 (out of 10) associated with fistula tract, discharge, or bowel movement.
Time frame: 12 weeks after surgery
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula (Part A)
Efficacy of E-CEL UVEC, as measured the rate of subjects presenting with relapse in treated fistula at week 24 Relapse is defined as meeting relapse criteria No.1 and one of the three sub-criteria of relapse criteria No.2 1. Reopening of internal opening a. Defined as visual confirmation of new aperture or interruption of the anal mucosa at the previously closed internal opening site, plus 2. Any one of the three (a, b, or c) sub-criteria immediately below: a. New discharge upon digital pressure i. Defined as expression of gas, fecal matter or pus upon gentle digital pressure over and around the external opening or site of closed external opening, but excluding serous or serosanguinous fluid, or b. Emergence of palpable mass at or adjacent to the fistulous tract, or c. Emergence of pain measured at VAS ≥ 50 (out of 100) or NRS ≥ 5 (out of 10) associated with fistula tract, discharge, or bowel movement.
Time frame: 24 weeks after surgery
E-CEL UVEC Treatment Success, as measured by the combination of cessation and absence of fistula leakage (Part A)
The success of E-CEL UVEC cells in subjects with anal fistulas will be assessed via digital pressure after completion of all treatments. (Applicable to all arms)
Time frame: 6 weeks after surgery
E-CEL UVEC Treatment Success, as measured by the combination of cessation and absence of fistula leakage (Part A)
The success of E-CEL UVEC cells in subjects with anal fistulas will be assessed via digital pressure after completion of all treatments. (Applicable to all arms)
Time frame: 12 weeks after surgery
E-CEL UVEC Treatment Success, as measured by the combination of cessation and absence of fistula leakage (Part A)
The success of E-CEL UVEC cells in subjects with anal fistulas will be assessed via digital pressure after completion of all treatments. (Applicable to all arms)
Time frame: 24 weeks after surgery
Assessment of number of adverse events (Part A)
Assessment of adverse events that include rates, description, and relatedness
Time frame: 6 weeks after surgery
Assessment of number of serious adverse events (Part A)
Assessment of serious adverse events that include rates, description, and relatedness
Time frame: 6 weeks after surgery
Assessment of number of adverse events (Part A)
Assessment of adverse events that include rates, description, and relatedness
Time frame: 12 weeks after surgery
Assessment of number of serious adverse events (Part A)
Assessment of serious adverse events that include rates, description, and relatedness
Time frame: 12 weeks after surgery
Assessment of number of adverse events (Part A)
Assessment of adverse events that include rates, description, and relatedness
Time frame: 24 weeks after surgery
Assessment of number of serious adverse events (Part A)
Assessment of serious adverse events that include rates, description, and relatedness
Time frame: 24 weeks after surgery
The cumulative number of treatment emergent adverse event (TEAE) (Part B)
The cumulative number of treatment emergent adverse event (TEAE) in all subjects assessed (also description of TEAE at visit WK 1 and according to number of treatments received)
Time frame: Week 1 after surgery
The cumulative number of treatment emergent adverse event (TEAE) (Part B)
The cumulative number of treatment emergent adverse event (TEAE) in all subjects assessed (also description of TEAE at visit WK 3 and according to number of treatments received)
Time frame: Week 3 after surgery
The cumulative number of treatment emergent adverse event (TEAE) (Part B)
The cumulative number of treatment emergent adverse event (TEAE) in all subjects assessed (also description of TEAE at visit WK 6 and according to number of treatments received)
Time frame: Week 6 after surgery
The cumulative number of treatment emergent adverse event (TEAE) (Part B)
The cumulative number of treatment emergent adverse event (TEAE) in all subjects assessed (also description of TEAE at visit WK 9 and according to number of treatments received)
Time frame: Week 9 after surgery
The cumulative number of treatment emergent adverse event (TEAE) (Part B)
The cumulative number of treatment emergent adverse event (TEAE) in all subjects assessed (also description of TEAE at visit WK 12 and according to number of treatments received)
Time frame: Week 12 after surgery
The cumulative number of treatment emergent adverse event (TEAE) (Part B)
The cumulative number of treatment emergent adverse event (TEAE) in all subjects assessed (also description of TEAE at visit WK 24 and according to number of treatments received)
Time frame: Week 24 after surgery
The rate of clinical response (CR) (Part B)
CR is defined as achieving all the following four criteria: 1\. Closure of internal opening * Defined as visual confirmation of normal mucosa (no interruption, redness or swelling) at the previous site of internal opening, plus 2. Closure of external tract * Defined as percutaneous blunt probe passage ≤ 30% of original tract length, plus 3. No discharge upon digital pressure * Defined as no fluid expression upon gentle digital pressure over and around the external opening or along the treated fistula tract, plus 4. No clinically meaningful pain * Defined by having no pain or mild pain measured as VAS ≤ 30 (out of 100) or NRS pain ≤ 3 (out of 10) . * Proportion of subjects achieving CR at WK 12 and 24 without fistula-related symptoms
Time frame: 12 Weeks after surgery
The rate of clinical response (CR) (Part B)
CR is defined as achieving all the following four criteria: 1\. Closure of internal opening * Defined as visual confirmation of normal mucosa (no interruption, redness or swelling) at the previous site of internal opening, plus 2. Closure of external tract * Defined as percutaneous blunt probe passage ≤ 30% of original tract length, plus 3. No discharge upon digital pressure * Defined as no fluid expression upon gentle digital pressure over and around the external opening or along the treated fistula tract, plus 4. No clinically meaningful pain * Defined by having no pain or mild pain measured as VAS ≤ 30 (out of 100) or NRS pain ≤ 3 (out of 10) . * Proportion of subjects achieving CR at WK 12 and 24 without fistula-related symptoms
Time frame: 24 Weeks after surgery
Proportion of subjects achieving CR without fistula-related symptoms (Part B)
Time frame: 24 weeks after surgery
The rate of sustained clinical response (Part B)
Sustained clinical response is defined as lasting 12 or more weeks
Time frame: 24 weeks after surgery
The rate of signs of healing (Part B)
'Signs of healing' is defined as "healed", "healing" or "not or lost heating" based on investigator assessment
Time frame: Up to 24 weeks after surgery
The rate of sustained signs of healing (Part B)
Sustained is defined as lasting 12 or more weeks
Time frame: Up to 24 weeks after surgery
The rate of (patient reported) symptom-free status (Part B)
"Symptom-free" is defined as absence of discharge, incontinence, flatulence, urge and fistula-related pain, as reported by the patient
Time frame: 24 weeks after surgery
The rate of the subjects presenting relapse (Part B)
Relapse is defined as meeting relapse criteria No.1 and one of the three sub-criteria of relapse criteria No.2 1. Reopening of internal opening a. Defined as visual confirmation of new aperture or interruption of the anal mucosa at the previously closed internal opening site, plus 2. Any one of the three (a, b, or c) sub-criteria immediately below: a. New discharge upon digital pressure i. Defined as expression of gas, fecal matter or pus upon gentle digital pressure over and around the external opening or site of closed external opening, but excluding serous or serosanguinous fluid, or b. Emergence of palpable mass at or adjacent to the fistulous tract, or c. Emergence of pain measured at VAS ≥ 50 (out of 100) or NRS ≥ 5 (out of 10) associated with fistula tract, discharge, or bowel movement.
Time frame: 24 weeks after surgery
The rate of refractory response (Part B)
The rate of refractory response (defined as no visible biological healing response and no improvement in fistula-related symptoms)
Time frame: 12 weeks after surgery
The rate of refractory response (Part B)
The rate of refractory response (defined as no visible biological healing response and no improvement in fistula-related symptoms)
Time frame: 24 weeks after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2026, 83 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →